DDInter416 DDInter224
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment.
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bosutinib
Clotrimazole {u} (Compound) binds {v} (Gene) CYP51A1
CYP51A1 {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Clotrimazole {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may lead to a major life threatening interaction when taken with {v} Bosutinib
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Clotrimazole {u} (Compound) binds {v} (Gene) CYP51A1
CYP51A1 {u} (Gene) regulates {v} (Gene) CSK
CSK {u} (Gene) is bound by {v} (Compound) Bosutinib
Clotrimazole {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Clotrimazole {u} (Compound) causes {v} (Side Effect) Oedema
Oedema {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bosutinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bosutinib
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Clotrimazole (Compound) binds CYP51A1 (Gene) and CYP51A1 (Gene) is upregulated by Bosutinib (Compound)
Clotrimazole (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Bosutinib (Compound)
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may lead to a major life threatening interaction when taken with Bosutinib
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gefitinib (Compound) and Gefitinib (Compound) resembles Bosutinib (Compound)
Clotrimazole (Compound) binds CYP51A1 (Gene) and CYP51A1 (Gene) regulates CSK (Gene) and CSK (Gene) is bound by Bosutinib (Compound)
Clotrimazole (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Gefitinib (Compound) and Gefitinib (Compound) resembles Bosutinib (Compound)
Clotrimazole (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)